We found that the BTSH signature was enriched in patients who responded to dual HER2 blockade, assessed as being normal-like at day 14 (Fig. 5B), pathological complete response at surgery (Fig. 5C) and residual cancer burden (RCB) score of 0-I at surgery (Fig. 5D). The gene discussed is ERBB2; the disease is cancer.